Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019

Shots:

• The P-IIIb/IV SPIRIT-H2H study results involve assessing of Taltz vs Humira (adalimumab) in 566 patients with PsA who are biologic DMARD-naive for 52wks.
• The P-IIIb/IV SPIRIT-H2H study results: met its 1EPs & 2Eps i.e, @24wks. reduction by 50% in disease activity as defined by ACR50; PASI100 (36% vs 28%) & superior to Humira, ACR50 (51% vs 47%); PASI100 (60% vs 47%) respectively, will be presented at EULAR
• Taltz is a mAb targeting IL-17A cytokine, act by inhibiting its interaction with the IL-17 receptor which is involved in inflammatory and immune responses and inhibits the release of pro-inflammatory cytokines and chemokines

Click here to read full press release/ article | Ref: Eli Lilly | Image: Wall Street Journal